Quarterly report pursuant to Section 13 or 15(d)

SETTLEMENT LIABILITY (Details Narrative)

v3.22.2.2
SETTLEMENT LIABILITY (Details Narrative) - USD ($)
$ in Thousands
9 Months Ended
Nov. 12, 2021
Sep. 30, 2022
Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]      
Restricted Cash   $ 5,338 $ 5,891
REGENXBIO [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Settlement Liabilities, Current $ 30,000    
Loss Contingency, Settlement Agreement, Terms (1) $20.0 million paid in November 2021 after execution of the Settlement Agreement, (2) $5.0 million on the first anniversary of the effective date of the Settlement Agreement, and (3) $5.0 million upon the earlier of (i) the third anniversary of the effective date of the Settlement Agreement or (ii) the closing of a Strategic Transaction, as defined in the Settlement Agreement    
Debt Instrument, Interest Rate, Stated Percentage   9.60%  
Restricted Cash   $ 5,000  
REGENXBIO [Member] | Due In November 2022 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Debt instrument maturity date   November 2022  
Long term debt   $ 4,900  
REGENXBIO [Member] | Due In November 2024 [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Debt instrument maturity date   November 2024  
Long term debt   $ 4,100